MRIGlobal will evaluate technologies and specimen processes to support the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH)
Kansas City, Mo. – MRIGlobal has been awarded a contract (Contract No. HHSN272201700001C) from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), to support its Mycobacterium tuberculosis (Mtb) Quality Assessment requirement (known as, “TBQA”).
Under the $13,704,858 (includes the Base Period and all options) contract, MRIGlobal will evaluate Mtb technologies and specimen processes to be used in NIAID-supported clinical investigations and disseminate TBQA technical and scientific data.
Additionally, MRIGlobal will assess the NIAID laboratory network capabilities to accurately and reliably perform study-specific Mtb tests. If any deficiencies are identified, MRIGlobal will advise and train laboratory and clinical site staff.
“We are honored to support NIAID in its research to better understand the development of Tuberculosis drug resistance,” said Roger K. Harris, Ph.D., MRIGlobal Vice President. “The opportunity builds upon our ongoing expertise in global health as it relates to detecting, preventing, and responding to infectious disease and antimicrobial resistance.”
Tuberculosis (TB) is a contagious and often severe airborne disease caused by infection with Mycobacterium tuberculosis bacteria. TB typically affects the lungs, but it can also affect any other organ of the body, and continues to be one of the major causes of disability and death worldwide.